Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 14 Carcinoma, Non-Small-Cell Lung 13 Neoplasms 10 Glioblastoma 9 Fallopian Tube Neoplasms 8 Colorectal Neoplasms 8 Breast Neoplasms 8 Lung Neoplasms 7 Rectal Neoplasms 6 Neoplasm Metastasis 6 Gliosarcoma 6 Colonic Neoplasms 6 Carcinoma, Renal Cell 6 Brain Neoplasms 6 Prostatic Neoplasms 4 Melanoma 4 Uterine Cervical Neoplasms 3 Solitary Fibrous Tumor, Pleural 3 Sarcoma, Alveolar Soft Part 3 Sarcoma 3 Mesothelioma, Malignant 3 Carcinoma, Hepatocellular 3 Breast Neoplasms, Male 3 Advanced Solid Tumor 3 Uveal Melanoma 2 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Pancreatic Neoplasms 2 Oligodendroglioma 2 Leukemia, Myeloid, Acute 2

Interventions

Doxorubicin 25 Gemcitabine 16 Trabectedin 12 Ifosfamide 12 Radiotherapy 11 Docetaxel 10 Dacarbazine 8 pazopanib 7 Nivolumab 6 Specimen Handling 5 Biopsy 5 liposomal doxorubicin 4 Temozolomide 4 pembrolizumab 3 Sunitinib 3 Sorafenib 3 Radiation 3 Magnetic Resonance Spectroscopy 3 Filgrastim 3 rucaparib 2 pegfilgrastim 2 olaratumab 2 eribulin 2 durvalumab 2 cixutumumab 2 cemiplimab 2 brostallicin 2 belinostat 2 avelumab 2 X-Rays 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Leiomyosarcoma × cediranib × Clear all

NCT03851614 2026-02-09

DAPPER

University Health Network, Toronto

Phase 2 Active not recruiting

Leiomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡